Suppr超能文献

通过荧光和圆二色性测量糖基化人血清白蛋白的药物结合特性。

Drug binding properties of glycosylated human serum albumin as measured by fluorescence and circular dichroism.

作者信息

Okabe N, Hashizume N

机构信息

Faculty of Pharmaceutical Sciences, Kinki University, Osaka, Japan.

出版信息

Biol Pharm Bull. 1994 Jan;17(1):16-21. doi: 10.1248/bpb.17.16.

Abstract

Binding properties of Sudlow's site-specific drugs to glycosylated human serum albumin (G-HSA) were investigated using fluorescence and circular dichroism (CD). Dansylamide, phenylbutazone and warfarin were used as site I-specific drugs, and dansylproline, ibuprofen and flufenamic acid were used as site II-specific ones. Similar changes in the fluorescence intensity of dansylamide occurred in the presence of both G-HSA and intact human serum albumin (HSA), while the fluorescence enhancement of dansylproline caused by G-HSA was extremely weakened in comparison with that by HSA. These results suggest that the glycosylation of HSA inhibits the binding of the site II-specific drug, dansylproline, to HSA, while it does not influence the binding of the site I specific drug, dansylamide. The induced ellipticities of the complexes of ibuprofen, flufenamic acid and phenyl butazone with G-HSA were diminished in comparison with those with HSA. With the complexes of warfarin, the induced ellipticity was enhanced. These CD results suggest that the glycosylation of HSA induces microenvironmental changes in the binding sites for the above site-specific drugs which influence the drug binding ability of HSA.

摘要

利用荧光和圆二色性(CD)研究了Sudlow位点特异性药物与糖基化人血清白蛋白(G-HSA)的结合特性。丹磺酰胺、保泰松和华法林用作位点I特异性药物,丹磺酰脯氨酸、布洛芬和氟芬那酸用作位点II特异性药物。在G-HSA和完整人血清白蛋白(HSA)存在的情况下,丹磺酰胺的荧光强度发生了类似的变化,而与HSA相比,G-HSA引起的丹磺酰脯氨酸的荧光增强极度减弱。这些结果表明,HSA的糖基化抑制了位点II特异性药物丹磺酰脯氨酸与HSA的结合,而不影响位点I特异性药物丹磺酰胺的结合。与HSA相比,布洛芬、氟芬那酸和保泰松与G-HSA形成的复合物的诱导椭圆率降低。对于华法林复合物,诱导椭圆率增强。这些CD结果表明,HSA的糖基化诱导了上述位点特异性药物结合位点的微环境变化,从而影响了HSA的药物结合能力。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验